Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

aap Implantate AG Issues Q3 FY 2012 Guidance; Confirms FY 2012 Outlook


Tuesday, 14 Aug 2012 02:17am EDT 

aap Implantate AG announced that for the third quarter of the fiscal year 2012 (Q3 FY 2012) it anticipates year-on-year sales growth of between 10% and 16% to between EUR 7.6 million and EUR 8.0 million and an EBITDA increase of between 13% and 15% to between EUR 0.9 million and EUR 1.2 million. Furthermore, the Company announced that it has reconfirmed its sales forecast of EUR 35.5 million (+22%) and its EBITDA forecast of EUR 5.2 million (+24%) for the fiscal year 2012. According to I/B/E/S Estimates, analysts on average are expecting the Company to report fiscal year 2012 revenue of EUR 35.60 million and fiscal year 2012 EBITDA of EUR 5.30 million. 

Company Quote

2.961
-0.029 -0.97%
11:36am EDT